Aug. 4 at 8:13 PM
📢
$HIMS Q2 Earnings Recap
Hims & Hers reported solid growth but missed slightly on top-line expectations 💊📉
💰 EPS:
$0.17 vs
$0.16 est → ✅ Beat by
$0.01
📉 Revenue:
$544.8M (+72.6% Y/Y) vs
$552M est → ❌ Miss by
$7.25M
🧾 Net Income:
$42.5M | Adj. EBITDA:
$82.2M
👥 Subscribers: 2.4M+ → 📈 +31% Y/Y
📆 Q3 Outlook:
Revenue:
$570M–
$590M (vs
$584M est)
Adj. EBITDA:
$60M–
$70M (margin: 11–12%)
📆 FY25 Outlook (unchanged):
Revenue:
$2.3B–
$2.4B
Adj. EBITDA:
$295M–
$335M (margin: 13–14%)
Shares dropped ~9% AH despite strong Y/Y growth and reaffirmed guidance 📉⚖️
#Hims #HIMS #Earnings #Telehealth #HealthcareTech
#DigitalHealth #StockMarket #Investing #EarningsSeason
#Teladoc
$TDOC #CVSHealth
$CVS #GoodRx
$GDRX #AmazonHealth
$AMZN